---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039782"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:58:07.766187+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Xenon appoints Dr. Gillian Cannon and Justin Gover to Board of Directors

## Summary
- Dr. Cannon brings 30+ years of pharma experience; held senior roles at Merck, UCB, Otsuka, and Roivant.
- Justin Gover was founding CEO of GW Pharma (sold for $7.2B) and led development of Epidiolex for epilepsy.
- Appointments effective August 8, 2023; both will receive standard non-employee director compensation.
- Their expertise aligns with Xenon's advancing XEN1101 in Phase 3 epilepsy trials and Phase 2 MDD study.

## SEC filing metadata
- accession: 0000950170-23-039782
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/0000950170-23-039782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/xene-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039782
- JSON: https://secwatch.observer/filing/0000950170-23-039782.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039782.txt

## Key facts
- Executive change
  Mr. Justin Gover was appointed as director at Xenon Pharmaceuticals Inc..
  - Action: appointed
  - Role: director
  source text: appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/0000950170-23-039782-index.htm
- Executive change
  Dr. Gillian Cannon was appointed as director at Xenon Pharmaceuticals Inc..
  - Action: appointed
  - Role: director
  source text: appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/0000950170-23-039782-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.